How are you taking part in this consultation?

You will not be able to change how you comment later.

You must be signed in to answer questions

  • Question on Consultation

    Has all of the relevant evidence been taken into account?

  • Question on Consultation

    Are the summaries of clinical and cost effectiveness reasonable interpretations of the evidence?

  • Question on Consultation

    Are the recommendations sound and a suitable basis for guidance to the NHS?

  • Question on Consultation

    Are there any equality issues that need special consideration and are not covered in the medical technology consultation document?

  • Question on Document

    We would like to draw your attention to the new minimum evidence standards section (section 5). Please consider it and comment on whether it reflects sufficient criteria for future NICE recommendations of digital technologies for supporting self-management of COPD.

  • Question on Document

    Are there any implementation considerations for digital technologies for supporting self-management of COPD that we may have missed?
The content on this page is not current guidance and is only for the purposes of the consultation process.

Evidence generation plan

Closed for comments This consultation ended on at   Request commenting lead permission

4 Monitoring

The companies must contact NICE:

  • within 6 months of publication of this plan to confirm agreements are in place to generate the evidence

  • annually to confirm that the data is being collected and analysed as planned.

The companies should tell NICE as soon as possible of anything that may affect ongoing evidence generation, including:

  • any substantial risk that the evidence will not be collected as planned

  • new safety concerns

  • the technologies significantly changing in a way that affects the evidence generation process.

If data collection is expected to end later than planned, the companies should contact NICE to arrange an extension to the evidence generation period. NICE reserves the right to withdraw the guidance if data collection is delayed, or if it is unlikely to resolve the evidence gaps.